risperidone has been researched along with Blood Pressure, High in 7 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Experiment 1: Wistar-Kyoto (WKY) rats, spontaneously hypertensive rats (SHRs) and stroke-prone SHRs (SHR-SPs) were treated with risperidone (0." | 7.78 | Risperidone enhances the vulnerability to stroke in hypertensive rats. ( Godfraind, T; Liu, C; Song, SW; Su, BL; Su, DF; Sun, Y; Yang, C, 2012) |
| "Risperidone has a relatively low risk of causing obesity and diabetes mellitus and is a first-line treatment for schizophrenia." | 7.74 | Glucose and lipid metabolism of long-term risperidone monotherapy in patients with schizophrenia. ( Hosoda, H; Inoue, T; Itoh, K; Izumi, T; Kangawa, K; Koyama, T; Kusumi, I; Murashita, M; Nakagawa, S; Tanaka, T, 2007) |
| "Our data show a potential pharmacokinetic interaction, most likely via CYP3A4 between amlodipine and RIS, reflected in significantly different C/Ds for RIS, 9-OH-RIS and AM." | 5.43 | Pharmacokinetic considerations in the treatment of hypertension in risperidone-medicated patients - thinking of clinically relevant CYP2D6 interactions. ( Gründer, G; Haen, E; Lammertz, SE; Paulzen, M; Schoretsanitis, G; Schruers, KR; Stegmann, B; Walther, S, 2016) |
| "Posterior reversible cerebral edema syndrome is a generally reversible neurologic condition that is diagnosed based on distinctive clinical and radiologic findings." | 5.40 | Arterial hypertension and posterior reversible cerebral edema syndrome induced by risperidone. ( Agostoni, C; Bianchetti, MG; Fossali, EF; Mauri, MC; Mazzoni, MB; Milani, GP; Triulzi, F, 2014) |
| "Experiment 1: Wistar-Kyoto (WKY) rats, spontaneously hypertensive rats (SHRs) and stroke-prone SHRs (SHR-SPs) were treated with risperidone (0." | 3.78 | Risperidone enhances the vulnerability to stroke in hypertensive rats. ( Godfraind, T; Liu, C; Song, SW; Su, BL; Su, DF; Sun, Y; Yang, C, 2012) |
| "Risperidone has a relatively low risk of causing obesity and diabetes mellitus and is a first-line treatment for schizophrenia." | 3.74 | Glucose and lipid metabolism of long-term risperidone monotherapy in patients with schizophrenia. ( Hosoda, H; Inoue, T; Itoh, K; Izumi, T; Kangawa, K; Koyama, T; Kusumi, I; Murashita, M; Nakagawa, S; Tanaka, T, 2007) |
| "Our data show a potential pharmacokinetic interaction, most likely via CYP3A4 between amlodipine and RIS, reflected in significantly different C/Ds for RIS, 9-OH-RIS and AM." | 1.43 | Pharmacokinetic considerations in the treatment of hypertension in risperidone-medicated patients - thinking of clinically relevant CYP2D6 interactions. ( Gründer, G; Haen, E; Lammertz, SE; Paulzen, M; Schoretsanitis, G; Schruers, KR; Stegmann, B; Walther, S, 2016) |
| "Data for 60,162 subjects with type 1 diabetes up to the age of 25 years registered in the nationwide German/Austrian Diabetes Survey were included in the analysis." | 1.42 | Comparison of glycemic and metabolic control in youth with type 1 diabetes with and without antipsychotic medication: analysis from the nationwide German/Austrian Diabetes Survey (DPV). ( Bartus, B; Bollow, E; Galler, A; Haberland, H; Holl, RW; Meusers, M; Näke, A; Schober, E, 2015) |
| "Posterior reversible cerebral edema syndrome is a generally reversible neurologic condition that is diagnosed based on distinctive clinical and radiologic findings." | 1.40 | Arterial hypertension and posterior reversible cerebral edema syndrome induced by risperidone. ( Agostoni, C; Bianchetti, MG; Fossali, EF; Mauri, MC; Mazzoni, MB; Milani, GP; Triulzi, F, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Milani, GP | 1 |
| Bianchetti, MG | 1 |
| Mazzoni, MB | 1 |
| Triulzi, F | 1 |
| Mauri, MC | 1 |
| Agostoni, C | 1 |
| Fossali, EF | 1 |
| Godman, B | 1 |
| Petzold, M | 1 |
| Bennett, K | 1 |
| Bennie, M | 1 |
| Bucsics, A | 1 |
| Finlayson, AE | 1 |
| Martin, A | 1 |
| Persson, M | 1 |
| Piessnegger, J | 1 |
| Raschi, E | 1 |
| Simoens, S | 1 |
| Zara, C | 1 |
| Barbui, C | 1 |
| Galler, A | 1 |
| Bollow, E | 1 |
| Meusers, M | 1 |
| Bartus, B | 1 |
| Näke, A | 1 |
| Haberland, H | 1 |
| Schober, E | 1 |
| Holl, RW | 1 |
| Paulzen, M | 1 |
| Haen, E | 1 |
| Gründer, G | 1 |
| Lammertz, SE | 1 |
| Stegmann, B | 1 |
| Schruers, KR | 1 |
| Walther, S | 1 |
| Schoretsanitis, G | 1 |
| Clark, D | 1 |
| Skrobot, OA | 1 |
| Adebiyi, I | 1 |
| Susce, MT | 1 |
| de Leon, J | 1 |
| Blakemore, AF | 1 |
| Arranz, MJ | 1 |
| Song, SW | 1 |
| Sun, Y | 1 |
| Su, BL | 1 |
| Liu, C | 1 |
| Yang, C | 1 |
| Godfraind, T | 1 |
| Su, DF | 1 |
| Murashita, M | 1 |
| Inoue, T | 1 |
| Kusumi, I | 1 |
| Nakagawa, S | 1 |
| Itoh, K | 1 |
| Tanaka, T | 1 |
| Izumi, T | 1 |
| Hosoda, H | 1 |
| Kangawa, K | 1 |
| Koyama, T | 1 |
7 other studies available for risperidone and Blood Pressure, High
| Article | Year |
|---|---|
Arterial hypertension and posterior reversible cerebral edema syndrome induced by risperidone.
Topics: Antipsychotic Agents; Brain Edema; Child; Female; Humans; Hypertension; Risperidone | 2014 |
Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications.
Topics: Adult; Antipsychotic Agents; Drug Prescriptions; Drugs, Generic; Europe; Health Resources; Humans; H | 2014 |
Comparison of glycemic and metabolic control in youth with type 1 diabetes with and without antipsychotic medication: analysis from the nationwide German/Austrian Diabetes Survey (DPV).
Topics: Adolescent; Adult; Albuminuria; Antipsychotic Agents; Blood Glucose; Body Mass Index; Diabetes Compl | 2015 |
Pharmacokinetic considerations in the treatment of hypertension in risperidone-medicated patients - thinking of clinically relevant CYP2D6 interactions.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Antipsychotic Agent | 2016 |
Apolipoprotein-E gene variants associated with cardiovascular risk factors in antipsychotic recipients.
Topics: Alleles; Antipsychotic Agents; Apolipoproteins E; Body Mass Index; Cardiovascular Diseases; Diabetes | 2009 |
Risperidone enhances the vulnerability to stroke in hypertensive rats.
Topics: Animals; Apoptosis; Cells, Cultured; Hypertension; Neurons; Rats; Rats, Inbred SHR; Rats, Inbred WKY | 2012 |
Glucose and lipid metabolism of long-term risperidone monotherapy in patients with schizophrenia.
Topics: Adiponectin; Adult; Antipsychotic Agents; Body Composition; Body Mass Index; Cholesterol, HDL; Femal | 2007 |